Panciera David L, Refsal Kent R, Sennello Kathleen A, Ward Daniel L
Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, VA 24061-0442, USA.
Am J Vet Res. 2006 Apr;67(4):599-603. doi: 10.2460/ajvr.67.4.599.
To evaluate the effects of deracoxib and aspirin on serum concentrations of thyroxine (T4), 3,5,3'-triiodothyronine (T3), free thyroxine (fT4), and thyroid-stimulating hormone (TSH) in healthy dogs.
24 dogs.
Dogs were allocated to 1 of 3 groups of 8 dogs each. Dogs received the vehicle used for deracoxib tablets (PO, q 8 h; placebo), aspirin (23 to 25 mg/kg, PO, q 8 h), or deracoxib (1.25 to 1.8 mg/kg, PO, q 24 h) and placebo (PO, q 8 h) for 28 days. Measurement of serum concentrations of T4, T3, fT4, and TSH were performed 7 days before treatment (day -7), on days 14 and 28 of treatment, and 14 days after treatment was discontinued. Plasma total protein, albumin, and globulin concentrations were measured on days -7 and 28.
Mean serum T4, fT4, and T3 concentrations decreased significantly from baseline on days 14 and 28 of treatment in dogs receiving aspirin, compared with those receiving placebo. Mean plasma total protein, albumin, and globulin concentrations on day 28 decreased significantly in dogs receiving aspirin, compared with those receiving placebo. Fourteen days after administration of aspirin was stopped, differences in hormone concentrations were no longer significant. Differences in serum TSH or the free fraction of T4 were not detected at any time. No significant difference in any of the analytes was detected at any time in dogs treated with deracoxib.
Aspirin had substantial suppressive effects on thyroid hormone concentrations in dogs. Treatment with high dosages of aspirin, but not deracoxib, should be discontinued prior to evaluation of thyroid function.
评估德拉考昔和阿司匹林对健康犬血清甲状腺素(T4)、三碘甲状腺原氨酸(T3)、游离甲状腺素(fT4)及促甲状腺激素(TSH)浓度的影响。
24只犬。
将犬分为3组,每组8只。犬分别接受德拉考昔片所用赋形剂(口服,每8小时1次;安慰剂)、阿司匹林(23至25毫克/千克,口服,每8小时1次)或德拉考昔(1.25至1.8毫克/千克,口服,每24小时1次)及安慰剂(口服,每8小时1次),持续28天。在治疗前7天(第-7天)、治疗的第14天和第28天以及停药后14天测定血清T4、T3、fT4和TSH浓度。在第-7天和第28天测定血浆总蛋白、白蛋白和球蛋白浓度。
与接受安慰剂的犬相比,接受阿司匹林的犬在治疗第14天和第28天时,血清T4、fT4和T3的平均浓度较基线水平显著降低。与接受安慰剂的犬相比,接受阿司匹林的犬在第28天时血浆总蛋白、白蛋白和球蛋白的平均浓度显著降低。停用阿司匹林14天后,激素浓度差异不再显著。在任何时间均未检测到血清TSH或T4游离部分的差异。在接受德拉考昔治疗的犬中,任何时间的任何分析物均未检测到显著差异。
阿司匹林对犬甲状腺激素浓度有显著抑制作用。在评估甲状腺功能之前,应停用高剂量阿司匹林治疗,但不应停用德拉考昔治疗。